BACKGROUND: The development of vaccines and therapeutics has relied on healthy volunteer influenza challenge studies. A validated human infection model with wild-type A(H1N1)pdm09 was reported previously. Our objective was to characterize a wild-type influenza A/Bethesda/MM1/H3N2 challenge virus in healthy volunteers. METHODS: Participants received a single dose of a cell-based, reverse-genetics, Good Manufacturing Practices-produced wild-type influenza A(H3N2)2011 virus intranasally and were isolated at the National Institutes of Health Clinical Center for ≥9 days. Dose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose). Viral shedding and clinical disease were evaluated daily. RESULTS: Of 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12 (32%) participants experiencing mild to moderate influenza disease (MMID), defined as shedding and symptoms. Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively. Symptom severity peaked on day 3, whereas most viral shedding occurred 1-2 days after challenge. Only 10 (29%) participants had a ≥4-fold rise in hemagglutination inhibition antibody titer after challenge. CONCLUSIONS: The A/Bethesda/MM1/H3N2 challenge virus safely induced MMID in healthy volunteers, but caused less MMID than the A(H1N1)pdm09 challenge virus even at the highest dose. There was less detection of shedding though the incidence of symptoms was similar to A(H1N1)pdm09. Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID indicate that preexisting immunity factors other than anti-HA antibody may limit shedding in healthy volunteers. This A/Bethesda/MM1/H3N2 challenge virus can be utilized in future studies to further explore pathogenesis and immunity and to evaluate vaccine candidates. CLINICAL TRIALS REGISTRATION: NCT02594189. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: The development of vaccines and therapeutics has relied on healthy volunteer influenza challenge studies. A validated humaninfection model with wild-type A(H1N1)pdm09 was reported previously. Our objective was to characterize a wild-type influenza A/Bethesda/MM1/H3N2 challenge virus in healthy volunteers. METHODS:Participants received a single dose of a cell-based, reverse-genetics, Good Manufacturing Practices-produced wild-type influenza A(H3N2)2011 virus intranasally and were isolated at the National Institutes of Health Clinical Center for ≥9 days. Dose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose). Viral shedding and clinical disease were evaluated daily. RESULTS: Of 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12 (32%) participants experiencing mild to moderate influenza disease (MMID), defined as shedding and symptoms. Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively. Symptom severity peaked on day 3, whereas most viral shedding occurred 1-2 days after challenge. Only 10 (29%) participants had a ≥4-fold rise in hemagglutination inhibition antibody titer after challenge. CONCLUSIONS: The A/Bethesda/MM1/H3N2 challenge virus safely induced MMID in healthy volunteers, but caused less MMID than the A(H1N1)pdm09 challenge virus even at the highest dose. There was less detection of shedding though the incidence of symptoms was similar to A(H1N1)pdm09. Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID indicate that preexisting immunity factors other than anti-HA antibody may limit shedding in healthy volunteers. This A/Bethesda/MM1/H3N2 challenge virus can be utilized in future studies to further explore pathogenesis and immunity and to evaluate vaccine candidates. CLINICAL TRIALS REGISTRATION: NCT02594189. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Entities:
Keywords:
H3N2; challenge; healthy volunteer; influenza A
Authors: Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman Journal: J Virol Date: 2007-10-17 Impact factor: 5.103
Authors: M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy Journal: J Virol Date: 1988-02 Impact factor: 5.103
Authors: John H Powers; Elizabeth D Bacci; M Lourdes Guerrero; Nancy Kline Leidy; Sonja Stringer; Katherine Kim; Matthew J Memoli; Alison Han; Mary P Fairchok; Wei-Ju Chen; John C Arnold; Patrick J Danaher; Tahaniyat Lalani; Michelande Ridoré; Timothy H Burgess; Eugene V Millar; Andrés Hernández; Patricia Rodríguez-Zulueta; Mary C Smolskis; Hilda Ortega-Gallegos; Sarah Pett; William Fischer; Daniel Gillor; Laura Moreno Macias; Anna DuVal; Richard Rothman; Andrea Dugas; Guillermo M Ruiz-Palacios Journal: Value Health Date: 2017-06-07 Impact factor: 5.725
Authors: Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli Journal: NPJ Vaccines Date: 2020-03-13 Impact factor: 7.344
Authors: Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores Journal: Clin Microbiol Rev Date: 2022-07-06 Impact factor: 50.129
Authors: Bryan T Mayer; Joshua T Schiffer; Ashish Goyal; Daniel B Reeves; Niket Thakkar; Mike Famulare; E Fabián Cardozo-Ojeda Journal: Sci Rep Date: 2021-06-04 Impact factor: 4.996
Authors: Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli Journal: NPJ Vaccines Date: 2020-03-13 Impact factor: 7.344
Authors: Henry T Hoffman; Robert M Miller; Jarrett E Walsh; Helen R Stegall; Daniel J Diekema Journal: Laryngoscope Investig Otolaryngol Date: 2020-07-29